Brain-Penetrant Allosteric α1A-AR Activators for Cognitive Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, such as amyloid immunotherapies, have shown disappointing results, and there is a need for therapeutics that can enhance synaptic function and neurogenesis to improve cognitive decline, as synaptic dysfunction is a significant factor in the initial stages of memory loss.
Innovation Solution
Development of compounds that selectively activate the Alpha1A-Adrenergic Receptor (α1A-AR) to enhance neurogenesis and synaptic plasticity, acting as positive allosteric modulators without causing side effects like increased blood pressure, and are capable of crossing the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If non-selective ligands are used to activate alpha1-adrenergic receptors, then cognitive function may be improved, but side effects such as increased blood pressure occur
Solution Approach 1:
The patent applies local quality by designing ligands with specific molecular characteristics that enable selective binding to alpha1A-adrenergic receptors in the brain while avoiding activation of other alpha1-AR subtypes (alpha1B and alpha1D) in peripheral tissues. This selectivity is achieved through optimized structural features including specific substituent patterns on the xanthine core, which confers brain penetration capability and subtype-specific affinity, thereby improving cognitive function without causing peripheral side effects like hypertension
Solution Approach 2:
The patent uses blood-brain barrier penetrating properties as an intermediary mechanism to deliver the selective alpha1A-AR ligand specifically to central nervous system targets. The molecular design incorporates features that facilitate active transport across the blood-brain barrier via the organic cation transporters (OCTs), ensuring that the therapeutic effect is localized to brain tissue while minimizing systemic exposure and peripheral side effects
2Reliability
If selective alpha1A-AR ligands are developed, then neuroprotection and cognitive enhancement are achieved, but drug delivery to the brain becomes more challenging
Solution Approach 1:
The patent applies parameter changes by systematically optimizing multiple molecular parameters of the xanthine-based ligands, including pKa values, molecular size, lipophilicity, and substituent patterns. These parameter optimizations are specifically tailored to enhance affinity for alpha1A-adrenergic receptors while simultaneously improving penetration through the blood-brain barrier. The structure-activity relationship studies identified specific parameter ranges that maximize both brain delivery and selective neuroprotective efficacy
Solution Approach 2:
The patent replaces passive diffusion mechanisms with active transport mechanisms for blood-brain barrier penetration. The ligand design incorporates cationic nitrogen atoms that enable recognition and transport by organic cation transporters (OCTs) located on the blood-brain barrier endothelium. This active transport mechanism provides more reliable and efficient brain delivery compared to passive diffusion, ensuring adequate therapeutic concentrations reach the central nervous system
3Adaptability or versatility
If chronic stimulation of alpha1B-AR subtype is used, then certain phenotypes are regulated, but apoptotic and neurodegenerative effects occur
Solution Approach 1:
The patent applies local quality by designing ligands with specific molecular characteristics that enable selective binding to alpha1A-adrenergic receptors in the brain while avoiding activation of other alpha1-AR subtypes (alpha1B and alpha1D) in peripheral tissues. This selectivity is achieved through optimized structural features including specific substituent patterns on the xanthine core, which confers brain penetration capability and subtype-specific affinity, thereby improving cognitive function without causing peripheral side effects like hypertension
Solution Approach 2:
The patent uses blood-brain barrier penetrating properties as an intermediary mechanism to deliver the selective alpha1A-AR ligand specifically to central nervous system targets. The molecular design incorporates features that facilitate active transport across the blood-brain barrier via the organic cation transporters (OCTs), ensuring that the therapeutic effect is localized to brain tissue while minimizing systemic exposure and peripheral side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds increase hippocampal neurogenesis, enhance long-term potentiation, and improve cognitive functions in Alzheimer's disease models, with no significant peripheral effects on blood pressure, offering a potential therapeutic approach for Alzheimer's disease and other neurological conditions.
Implementation Method 1
acting as positive allosteric modulators
Data Source
AI summary
The present invention relates to compounds that are activators of the Alpha1A-Adrenergic Receptor (α1A-AR) and methods of using such compounds: for treating neurological conditions, for cardio-protection, and for treating other conditions. In certain embodiments, the α1A-AR activator compound is a compound of Formula I. In certain embodiments, the neurological condition is Alzheimer's disease, benign prostatic hyperplasia, memory loss, depression, or Parkinson's disease.